Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial.

Trial Profile

Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Olaparib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms STOMP
  • Most Recent Events

    • 11 Feb 2016 Accural to date is 100% as reported by United Kingdom Clinical Research Network.
    • 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United kingdom Clinical Research Network.
    • 11 Feb 2016 Planned End Date changed from 19 Sep 2015 to 11 Dec 2015 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top